152 related articles for article (PubMed ID: 9323816)
1. Biocompatibility reflected by haemostasis variables during cardiopulmonary bypass using heparin-coated circuits.
Borowiec J; Bagge L; Saldeen T; Thelin S
Thorac Cardiovasc Surg; 1997 Aug; 45(4):163-7. PubMed ID: 9323816
[TBL] [Abstract][Full Text] [Related]
2. Haemostasis at low heparin dosage during cardiopulmonary bypass with heparin-coated circuits in pigs.
Bagge L; Borowiec JW; Thelin S; Hultman J
Scand Cardiovasc J; 1997; 31(5):275-81. PubMed ID: 9406294
[TBL] [Abstract][Full Text] [Related]
3. Haemostasis at low heparin dosage during cardiopulmonary bypass with heparin-coated circuits in pigs.
Bagge L; Borowiec JW; Thelin S; Hultman J
Scand Cardiovasc J; 1997; 31(6):275-81. PubMed ID: 9498931
[TBL] [Abstract][Full Text] [Related]
4. Heparinized cardiopulmonary bypass and full heparin dose marginally improve clinical performance.
Ovrum E; Am Holen E; Tangen G; Ringdal MA
Ann Thorac Surg; 1996 Oct; 62(4):1128-33. PubMed ID: 8823101
[TBL] [Abstract][Full Text] [Related]
5. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
Muehrcke DD; McCarthy PM; Kottke-Marchant K; Harasaki H; Pierre-Yared J; Borsh JA; Ogella DA; Cosgrove DM
J Thorac Cardiovasc Surg; 1996 Aug; 112(2):472-83. PubMed ID: 8751516
[TBL] [Abstract][Full Text] [Related]
6. Deleterious effects of cardiopulmonary bypass on early graft function after single lung allotransplantation: evaluation of a heparin-coated bypass circuit.
Francalancia NA; Aeba R; Yousem SA; Griffith BP; Marrone GC
J Heart Lung Transplant; 1994; 13(3):498-507. PubMed ID: 8061027
[TBL] [Abstract][Full Text] [Related]
7. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass.
Chan AK; Leaker M; Burrows FA; Williams WG; Gruenwald CE; Whyte L; Adams M; Brooker LA; Adams H; Mitchell L; Andrew M
Thromb Haemost; 1997 Feb; 77(2):270-7. PubMed ID: 9157580
[TBL] [Abstract][Full Text] [Related]
8. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study.
Borowiec J; Thelin S; Bagge L; Nilsson L; Venge P; Hansson HE
J Thorac Cardiovasc Surg; 1992 Sep; 104(3):642-7. PubMed ID: 1325013
[TBL] [Abstract][Full Text] [Related]
9. Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery.
Chomiak PN; Walenga JM; Koza MJ; Reilly TM; Turlapathy P; Pifarre R
Circulation; 1993 Nov; 88(5 Pt 2):II407-12. PubMed ID: 7993389
[TBL] [Abstract][Full Text] [Related]
10. Clinical heparin coated cardiopulmonary bypass: reduction of systemic heparin requirements for redo cardiac surgery.
Ladowski JS; Schatzlein MH; Peterson AC; Deschner WP; Matheis R; Ellenwood M; Bach J; Moldovan L; McKamey D
ASAIO J; 1996; 42(1):34-6. PubMed ID: 8808455
[TBL] [Abstract][Full Text] [Related]
11. Heparin-coated cardiopulmonary bypass circuits in coronary bypass surgery.
Horimoto H; Kondo K; Asada K; Sasaki S
Artif Organs; 1996 Aug; 20(8):936-40. PubMed ID: 8853810
[TBL] [Abstract][Full Text] [Related]
12. [The evaluation of the bio-compatibility and the clinical usefulness of heparin-coated cardiopulmonary bypass circuits].
Yamanaka J; Takeuchi Y; Torii S; Gomi A; Nakatani H; Kohno K
Nihon Kyobu Geka Gakkai Zasshi; 1996 Jan; 44(1):47-53. PubMed ID: 8683171
[TBL] [Abstract][Full Text] [Related]
13. A comparative evaluation of the effect of pump type and heparin-coated surfaces on platelets during cardiopulmonary bypass.
Misoph M; Babin-Ebell J; Schwender S
Thorac Cardiovasc Surg; 1997 Dec; 45(6):302-6. PubMed ID: 9477463
[TBL] [Abstract][Full Text] [Related]
14. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment.
Fukutomi M; Kobayashi S; Niwaya K; Hamada Y; Kitamura S
Artif Organs; 1996 Jul; 20(7):767-76. PubMed ID: 8828766
[TBL] [Abstract][Full Text] [Related]
15. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis.
Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M; Oystese R
Eur J Cardiothorac Surg; 1996; 10(6):449-55. PubMed ID: 8817142
[TBL] [Abstract][Full Text] [Related]
16. Heparin-coated cardiopulmonary bypass circuits reduce blood cell trauma. Experiments in the pig.
Thelin S; Bagge L; Hultman J; Borowiec J; Nilsson L; Thorelius J
Eur J Cardiothorac Surg; 1991; 5(9):486-91. PubMed ID: 1931093
[TBL] [Abstract][Full Text] [Related]
17. [Experimental study on heparin-free cardiopulmonary bypass using nafamostat mesilate (FUT-175) and heparin-coated circuit].
Takano H; Miyamoto Y; Kaneko M; Matsuwaka R; Kuratani T; Amemiya A; Nakano S; Matsuda H
Nihon Kyobu Geka Gakkai Zasshi; 1993 Nov; 41(11):2166-73. PubMed ID: 8283086
[TBL] [Abstract][Full Text] [Related]
18. Effects of heparin coating of cardiopulmonary bypass circuits on in vitro oxygen free radical production during coronary bypass surgery.
Bozdayi M; Borowiec J; Nilsson L; Venge P; Thelin S; Hansson HE
Artif Organs; 1996 Sep; 20(9):1008-16. PubMed ID: 8864022
[TBL] [Abstract][Full Text] [Related]
19. Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery.
Spiess BD; Vocelka C; Cochran RP; Soltow L; Chandler WL
J Cardiothorac Vasc Anesth; 1998 Jun; 12(3):299-304. PubMed ID: 9636912
[TBL] [Abstract][Full Text] [Related]
20. Heparin-coated circuits reduce the formation of TNF alpha during cardiopulmonary bypass.
Yamada H; Kudoh I; Hirose Y; Toyoshima M; Abe H; Kurahashi K
Acta Anaesthesiol Scand; 1996 Mar; 40(3):311-7. PubMed ID: 8721461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
